The effect of lipocortin 1 on neutrophil deformability

Citation for published version:

Digital Object Identifier (DOI):
10.1155/S0962935196000257

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Mediators of Inflammation

Publisher Rights Statement:
Copyright © 1996 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
LIPOCORTIN 1 (LC1) is an anti-inflammatory protein, which, given systemically, inhibits polymorphonuclear neutrophil (PMN) emigration from the circulation to sites of inflammation; delivery of LC1 to the inflamed site is ineffective. We have examined the effect of LC1 on changes in PMN deformability, and observed a consistent improvement in the deformability of unstimulated PMN; N-formyl-methionyl-leucyl-phenylalanine (fMLP)-activated cell deformability was unaltered. A LC1-induced increase in cell deformability may reduce PMN sequestration so contributing to the anti-migratory effects of systemic LC1 previously demonstrated in vivo.

The effect of lipocortin 1 on neutrophil deformability

E. M. Drost, W. MacNee and S. F. Smith

1Department of Medicine, Rayne Laboratory, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, UK; and 2Department of Medicine, Charing Cross and Westminster Medical School, Fulham Palace Road, London W6 8RF, UK

Introduction

Glucocorticoids are powerful anti-inflammatory drugs capable of modulating both cellular and soluble components of the inflammatory response. In this investigation we have studied an anti-inflammatory, glucocorticoid-inducible protein, lipocortin 1 (LC1, annexin 1), which mediates a number of glucocorticoid actions including inhibition of PMN emigration to sites of inflammation. The mechanism of this action has not been fully elucidated, but could include effects on PMN rolling adhesion, expression of adhesion molecules, or diapedesis, since, to reach a site of inflammation, circulating PMN must slow down, adhere to the endothelium and migrate between the endothelial cells.

Most previous studies suggest that glucocorticoids and LC1 do not directly alter expression of PMN or endothelial cell adhesion molecules, an exception being Cronstein and colleagues who demonstrated that glucocorticoids diminish ELAM-1 and ICAM-1 expression on LPS-stimulated endothelium, although these changes appear to be both time and stimulus-dependent.

Although the details of extravasation are thought to vary between the systemic and pulmonary circulations, a reduction in cell deformability can prolong the transit time of PMN through the microvasculature, thus increasing opportunities for selectin-mediated rolling adhesion of PMN to endothelial cells, this being a prerequisite under shear conditions for the leukocyte firm (CD11/CD18-mediated) adhesion which is required for PMN emigration. Therefore, the aim of the present study was to investigate the effect of LC1 on PMN deformability.

Materials and Methods

Recombinant human LC1 (rhLC1) was the generous gift of Dr J. L Browning, Biogen Inc., Cambridge, MA. PMN populations (n = 9; > 96.9 ± 2.2% pure) were harvested from peripheral venous blood as described previously.

Cell suspensions were pre-incubated with rhLC1 dissolved in PBS containing 1 mg human serum albumin/ml for 30 min at 37°C at a concentration of 2 µg/10⁶ cells/ml after which the cells remained > 98% viable. LC1 binds to human peripheral blood leukocytes in a dose-dependent manner; the cell surface binding sites on PMN are approximately 80% saturated at the concentration of LC1 and the temperature used in the present study. Biologically inactive rhLC1 was used as a control.

Cell deformability was assessed in the presence and absence of 10⁻⁷ M N-formyl-methionyl-leucyl-phenylalanine (fMLP), by filtration of PMN suspensions (1 x 10⁵/ml PBS containing 5% albumin) at constant flow through a Nucleopore polycarbonate membrane (5 µm diameter pores). The more rigid the cells, the longer they take to enter and pass through the pores resulting in a higher pressure. Hence, the pressure developed by a cell suspension over 6 min filtration compared to the pressure of PBS alone was measured as an indicator of cell deformability.

Statistics: Differences between treatments were assessed using a one-way analysis of variance.
Effect of lipocortin 1 on neutrophil deformability

Results

Following pre-incubation with functional rhLcl, passive PMN from every subject (n = 9) showed increased deformability compared to control cells at each time point examined up to 6 min filtration (Fig. 1). However, no change in PMN deformability was observed in the presence of biologically inactive rhLcl (6 min pressure; control, 3.09 ± 0.68 cm H2O; n = 5; mean ± S.E.M.; p > 0.05 ANOVA).

When PMN were stimulated with fMLP (6 min pressure; fMLP, 8.03 ± 1.33 cm H2O) their deformability was significantly reduced compared to unstimulated cells (6 min pressure; control, 3.09 ± 0.68 cm H2O). Neither pre-incubation with functional nor inactive rhLcl had a consistent or significant effect on PMN deformability in the presence of fMLP (6 min pressure; fMLP + rhLcl, 8.49 ± 1.0 cm H2O; fMLP + inactive rhLcl, 10.12 ± 0.7 cm H2O; n = 5; p > 0.05 ANOVA).

Examination of PMN by light microscopy confirmed that no cell aggregation occurred with any treatment regimen, and thus the pressures generated were indeed a reflection of cell deformability.

Discussion

In this study we observed that incubation of passive PMN with rhLcl in vitro resulted in a consistent increase in cell deformability, which occurred only when the protein was in its correct, three-dimensional conformation. The dimensions of the microvasculature impose a restraint on PMN passage, particularly in the pulmonary capillaries. The disparity between the diameters of circulating PMN (6–8 μm) and the systemic (6 μm) or pulmonary (5 μm) capillaries require that the cells must deform during capillary transit (reviewed in Reference 10). Thus, the more deformable the cell, the more rapid the transit through the capillary beds, the briefer the contact with the endothelium and the fewer the opportunities for the PMN to adhere prior to migrating out of the circulation. Hence, a Lc1-induced increase in cell deformability may decrease sequestration of PMN in the capillary bed; this mechanism could contribute to the reduction by intravenous Lc1 of experimentally induced neutropenia in vivo.11

Interestingly, when PMN were activated with fMLP, Lc1 had no effect on cell deformability. This is consistent with observations in vivo which have shown that whilst systemic Lc1 reduces the migration of (passive) circulating neutrophils, Lc1 administered directly to a site of inflammation has no effect on (activated) migrated PMN.11

How Lc1 causes the observed change in the mechanical properties of PMN is currently unknown. PMN deformability is determined mainly by the intracellular levels, conformation and distribution of filamentous (F) actin. Lc1 can bind F-actin 12 and thus might directly modify the conformation and/or distribution of this cytoskeletal protein. However, the effect of Lc1 on PMN deformability may potentially be mediated by changes in signal transduction since studies on A549 cells demonstrate that Lc1 can inhibit G-protein-mediated activation of arachidonic acid release.13 However, as Lc1 treatment did not affect the deformability of activated PMN in our study, this mechanism seems less likely to explain the observation reported here. We plan to investigate the effect of Lc1 on F-actin in PMN more fully.

References


ACKNOWLEDGEMENTS. We thank Dr T. Tetley for helpful comments on the manuscript. A Wellcome Travel Grant made to S.F.S. facilitated the writing up of the study.

Received 12 December 1995; accepted 22 February 1996